REGN News and Press, Regeneron Pharmaceuticals Inc. From 02/28/24

2024-02-28 11:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 3.3% to $4.09 on volume of 136,598,120 shares Nikola Corporation (NKLA) rose 8.9% to $0.7643 on volume of 134,299,966 shares Rivian Automotive Inc. (RIVN) fell 12.1% to $10.07 on...

2024-02-23 05:40:38 ET Sanofi ( NASDAQ: SNY ) and partner Regeneron Pharmaceuticals ( NASDAQ: REGN ) announced Friday the receipt of priority review for their supplemental biologics license application (sBLA) for Dupixent (dupilumab), an anti-inflammatory medication.... ...

Priority Review granted based on positive results from two Phase 3 trials; i f approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in more than a decade Regulatory submissions are also under review in China and Europe ...

2024-02-21 10:00:00 ET Those looking to invest in stocks can sometimes seem spoiled for choices. There are all kinds of businesses in the equity markets that seem intriguing. However, upon closer inspection, many of these corporations don't actually prove worthy of investors' time or money....

2024-02-21 08:14:13 ET Regeneron ( NASDAQ: REGN ) announced Wednesday that the FDA granted priority review for its Biologics License Application (BLA) seeking U.S. market access for its multiple myeloma therapy linvoseltamab.... Read the full article on Seeking Alpha For...

2024-02-21 07:13:01 ET Regeneron ( NASDAQ: REGN ) and Vertex Pharmaceuticals ( NASDAQ: VRTX ) have crossed $100B in market capitalization for the first time, joining two other giants in the biotech industry, Amgen ( AMGN ) and AbbVie ( ABBV ).... Read the full ...

TARRYTOWN, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for linvoseltamab to treat adult patients with relapsed/...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of today's top gainers. The company's shares have moved 1.15% on the day to $958.96. Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The compa...

2024-02-17 18:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...